药师参与对慢性阻塞性肺疾病患者治疗依从性及疗效的影响

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (0 KB) HTML (36 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨药师参与慢性阻塞性肺疾病（COPD）患者管理对其依从性及疗效的影响。方法选取2018年12月～2019年5月江西省丰城市中医院收治的60 例COPD 患者作为研究对象，按照随机数字表法将其分为研究组与对照组，每组各30 例。对照组患者采用常规管理模式，研究组患者采用药师参与管理，两组患者的干预时间均为14 d。干预结束后比较两组患者的病情控制情况、用药依从性、不良反应、治疗效果以及自我管理能力。结果干预前，两组患者的慢性阻塞性肺疾病评估测试（CAT）评分及依从性评分比较，差异无统计学意义（P＞0.05）；干预后，两组患者依从性评分高于干预前，CAT 评分低于干预前，差异均有统计学意义（P＜0.05）；干预后，研究组患者的依从性评分高于对照组，CAT 评分低于对照组，差异有统计学意义（P＜0.05）。研究组患者的药物不良反应总发生率低于对照组，差异有统计学意义（P＜0.05）。研究组患者的住院时间短于对照组，住院费用以及住院次数低于对照组，差异有统计学意义（P＜0.05）。干预前，两组患者的自我管理能力评分比较，差异无统计学意义（P＞0.05）；干预后，两组患者的自我管理能力评分高于干预前，差异有统计学意义（P＜0.05）；干预后，研究组患者的自我管理能力评分均高于对照组，差异有统计学意义（P＜0.05）。结论药师参与COPD 患者管理能够有效提高患者的依从性，减少用药差错，降低药品不良反应总发生率，缩短住院时间，降低医疗费用，提高患者的自我管理意识和能力，减少住院次数。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	谢跃辉
	袁琴
	杨悟新

关键词 ：药师, 慢性阻塞性肺疾病患者管理, 依从性, 疗效

Abstract：Objective To explore the impact of pharmacist participation in the management of patients with chronic obstructive pulmonary disease (COPD) on compliance and efficacy. Methods A total of 60 patients with COPD who were admitted to Fengcheng Hospital of Traditional Chinese Medicine in Jiangxi Province from December 2018 to May 2019 were selected as the research objects and divided into the study group and the control group according to the random number table method, with 30 cases in each group. The control group adopted the conventional management mode, and the study group adopted the pharmacist to participate in the management. The intervention time of the two groups was 14 days. After the intervention, the cognitive score of medication safety ability, disease control, medication compliance,adverse reactions, treatment effect and self-management ability were compared between the two groups. Results Before intervention, there were no statistically significant differences in COPD assessment test (CAT) score and compliance score between the two groups (P＞0.05). After intervention, the compliance scores of the two groups were higher than those before the intervention, the CAT score was lower than that before the intervention, and the differences were statistically significant (P＜0.05). After intervention, the compliance scores in the study group were higher than those in the control group, and the CAT score was lower than that in the control group, and the differences were statistically significant (P＜0.05). The total incidence of adverse drug reactions in the study group was lower than that in the control group,and the difference was statistically significant (P＜0.05).The length of stay in the study group was shorter than that in the control group, and the hospitalization cost and hospitalization times were lower than those in the control group, the differences were statistically significant (P＜0.05).Before intervention, there was no statistical significance in the score of self-management ability between the two groups(P＞0.05). After intervention, the scores of self-management ability of patients in two groups were higher than those before intervention, and the differences were statistically significant (P＜0.05). After intervention, the scores of self-management ability in the study group were all higher than those in the control group, and the differences were statistically significant (P＜0.05). Conclusion The participation of pharmacists in the management of COPD patients can effectively improve patients′ compliance, reduce medication errors, reduce the total incidence of adverse drug reactions, shorten hospital stays, reduce medical expenses, improve patient self-management awareness and ability, and reduce the number of hospitalizations.

Key words： Pharmacist Management of patients with chronic obstructive pulmonary disease Compliance Efficacy

收稿日期: 2020-09-23

基金资助:江西省宜春市社会发展领域科技支撑计划项目（JXYC2019KSA037）

引用本文:

谢跃辉；袁琴；杨悟新. 药师参与对慢性阻塞性肺疾病患者治疗依从性及疗效的影响[J]. 中国当代医药, 2021, 28(12): 18-021.
XIE Yue-hui； YUAN Qin； YANG Wu-xin. Influence of pharmacist participation on the treatment compliance and efficacy of patients with chronic obstructive pulmonary disease. 中国当代医药, 2021, 28(12): 18-021.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2021/V28/I12/18

[1]	董小芬，丁美佳，杨小凤.护理干预应用于COPD 的疗效观察[J].中国卫生标准管理，2017，8（24）：172-174.
[2]	陆卫芬，陈文宇，方志仙，等.呼吸慢病管理平台在C、D 组稳定期COPD 患者康复中的应用研究[J].中国现代医生，2020，58（12）：82-86.
[3]	滕野，曲艳红.COPD 急性加重期住院患者健康教育对COPD 慢病管理影响的研究[J].中国保健营养，2019，29（31）：51-52.
[4]	中华医学会呼吸病学分会COPD 学组.COPD 基层诊治指南（2018年）[J].中华全科医师杂志，2018，11（17）：856-870.
[5]	郭珩，邓体瑛，余雄杰，等.COPD 患者全程化药学服务模式的建立与效果评价[J].药物流行病学杂志，2018，27（6）：414-418.
[6]	施芳红，李浩，王丽华，等.临床药师参与糖尿病患者分级诊疗模式探讨[J].中国药师，2017，2（7）：1286-1288.
[7]	肖甜，陈晓英，王娜，等.中国大城市社区慢性阻塞性肺部疾病患者药物使用现状研究[J].中华流行病学杂志，2017，38（2）：142-146.
[8]	吴秋惠，张桂凡，杨凡，等.药师指导正确使用吸入剂对提高哮喘治疗的作用[J].药学与临床研究，2016，12（1）：81-82.
[9]	史卫卫，刘璐，张帆，等.慢性阻塞性肺疾病患者CAT 评分与病情评估指标的相关性分析[J].老年医学与保健，2018，24（3）：257-261.
[11]	张彩虹，何国平，李继平，等.COPD 患者自我管理量表的编制与考评[J].中国全科医学，2011，14（28）：3219-3223.
[12]	张楠，张娜，鲁秀玲，等.医联体药师团队参与COPD 患者长期用药安全评估管理工作模式的实践研究[J].中国药师，2018，21（3）：441-444.
[13]	刘海燕.COPD 康复期患者自我管理能力的影响因素与护理对策[J].护理实践与研究，2019，16（10）：12-14.
[14]	王玥.COPD 稳定期患者应用肺康复训练联合心理干预对其生存质量的影响分析[J].国际医药卫生导报，2019，25（4）：622-625.
[10]	Morisky DE，Green LW，Levine DM.Concurrent and predictive validity of a self-reported measure of medication adherence[J].Med Care，1986，24（1）：67-74.
[15]	纵单单，陈平.COPD 防治全球倡议2017 更新要点解读[J].中华结核和呼吸杂志，2017，4（5）：380-385.